Investment Rating - The report maintains an "Outperform" rating for China Feihe [2][15]. Core Insights - The company reported total revenue of RMB 18.11 billion for 2025, a decrease of 12.7% year-over-year, and a net profit attributable to shareholders of RMB 1.94 billion, down 45.7% year-over-year, which fell short of market expectations [3][11]. - In the second half of 2025, revenue was RMB 8.96 billion, down 15.9% year-over-year, while net profit attributable to shareholders was RMB 940 million, down 44.6% year-over-year, although the decline in profits narrowed and operating margins improved [3][11]. - The company has proactively optimized channel inventory and controlled shipment schedules since May 2025, which, along with reduced government subsidies and impairment of biological assets, has placed short-term pressure on performance. However, following inventory destocking, fundamentals have strengthened, laying the foundation for profit recovery [3][11]. Revenue and Profit Forecast - Revenue is projected to be RMB 18.73 billion, RMB 19.47 billion, and RMB 20.36 billion for 2026, 2027, and 2028, respectively, with net profit attributable to shareholders expected to be RMB 2.41 billion, RMB 2.57 billion, and RMB 2.76 billion for the same years [5][15]. - The estimated diluted EPS for 2026, 2027, and 2028 is RMB 0.27, RMB 0.28, and RMB 0.30, respectively [5][15]. Business Structure and Growth - The business structure continues to optimize, with the core infant formula business generating RMB 15.87 billion, accounting for 87.6% of total revenue, and maintaining a market share of 19% [4][12]. - New product launches have shown promising results, with the newly launched products Jiecu and Qicu generating over RMB 69 million in revenue within a month of their release [4][12]. - The company is expanding its overseas business, with revenue from the U.S. and Canada reaching RMB 180 million and RMB 50 million, respectively, showing year-over-year growth of 11.7% and 23.3% [4][12]. Cost Management and Financial Health - The consolidated gross margin for the year was 65.0%, down 1.3 percentage points year-over-year, primarily due to an increased proportion of low-margin raw material powder revenue. However, the gross margin for infant formula powder improved to 73.5%, up 2.2 percentage points year-over-year [13]. - The company holds net cash of RMB 16.2 billion, indicating robust operating cash flow [13][14].

Core Viewpoint - The company reported a decline in revenue and net profit for 2025, with a focus on adjusting its infant formula business and expanding its lifecycle nutrition system in response to increased competition and weak demand [1][2]. Financial Performance - In 2025, the company achieved a main revenue of 18.113 billion yuan, down 12.7% year-on-year, and a net profit of 1.939 billion yuan, down 45.7% year-on-year [1]. - For the second half of 2025, the main revenue was 8.962 billion yuan, a decrease of 15.9% year-on-year, and net profit was 939 million yuan, down 44.6% year-on-year [1]. - The company proposed a final dividend of 0.129 HKD per share, along with a mid-term dividend of 0.1209 HKD, totaling a dividend payout of 2.03 billion yuan for 2025, with a dividend rate of 104.85% [1]. Market Dynamics - The infant formula sector faced weak demand and intensified competition, with newborn numbers declining to 7.92 million after a brief recovery in 2024 [1]. - The company's market share in the infant formula industry decreased to 19% in 2025 from 20.5% in 2024 [2]. Product Performance - Key products such as Xingfeifan, Zhuorui, and Zhuoyao generated revenues of 4.3 billion, 6.5 billion, and 710 million yuan respectively, with Zhuorui showing a relatively stable performance with a 3% decline [1]. - The company’s gross margin improved significantly to 68.52% in the second half of 2025, up 3.63 percentage points year-on-year, attributed to cost savings from in-house production of core raw materials [1]. Strategic Initiatives - The company is actively adjusting its infant formula offerings by launching new products and enhancing operational strategies, including a focus on international markets [2]. - Plans for 2026 include launching high-end goat milk powder and customized products, as well as expanding into North America, Mexico, and Indonesia [2]. - The company aims to develop a lifecycle nutrition system, targeting revenue of 300 million yuan from children's nutrition products and 400 million yuan from adult functional nutrition by 2026 [3]. Investment Outlook - The company is expected to see some recovery in operations in 2026, with projected revenues of 2.46 billion, 2.56 billion, and 2.65 billion yuan for 2026-2028 [3]. - The current dividend yield is 6.8%, providing a degree of certainty in returns, with a target valuation of 14 times earnings, corresponding to a target price of 4.3 HKD [3].

Investment Rating - The report maintains an "Accumulate" rating for China Feihe (6186.HK) with a current price of HKD 3.68 [1] Core Insights - In 2025, China Feihe achieved revenue of CNY 18.11 billion, a year-on-year decrease of 12.7%, and a net profit attributable to shareholders of CNY 1.94 billion, down 45.7% [4][5] - The infant formula business, which accounts for 88% of total revenue, faced pressure due to declining birth rates and increased competition, resulting in a revenue decline of 16.8% [5] - Despite challenges, the company remains a market leader with a 19% market share and high brand recognition [5] - New high-end products launched in 2025 have shown promising performance and are expected to contribute to revenue growth [5][8] - The company plans to maintain a high dividend policy, distributing no less than CNY 2 billion in dividends for 2025 [7] Financial Performance Summary - Revenue and profit forecasts for 2026-2028 have been adjusted downwards due to weak demand for infant formula, with projected net profits of CNY 2.29 billion in 2026 and CNY 2.45 billion in 2027 [8][11] - The overall gross margin for 2025 was 65.0%, a decrease of 1.3 percentage points, primarily due to an increase in low-margin raw material sales [7] - The company has a strong cash flow position, with operating cash flow projected to improve in the coming years [13] Market Expansion - In 2025, overseas revenue reached CNY 230 million, with significant growth in the Canadian market, where the company received its first foreign infant formula production license [8] - Plans for 2026 include entering the U.S. and Mexican markets, further expanding North American operations [8] Valuation and Earnings Forecast - The current stock price corresponds to a price-to-earnings ratio of 13x for 2026, 12x for 2027, and 11x for 2028, indicating a favorable valuation for a leading player in the domestic milk powder industry [8][11]

Core Viewpoint - The article emphasizes the need for improving the quality and quantity of protein intake among the Chinese population, highlighting the structural issues in the dairy industry, including insufficient deep processing capabilities and reliance on imported raw materials [2][3]. Group 1: Protein Intake Issues - The current protein intake level in China is inadequate, particularly in terms of high-quality protein, with an average daily intake of 60.4g compared to 93.9g in the U.S. and 71.4g in Japan [4][6]. - Over 55% of parents report that their children consume a limited variety of protein sources, and nearly 90% of elderly individuals reduce their protein intake due to health misconceptions, leading to serious health issues like sarcopenia [6][8]. - There is a significant gap in consumer awareness regarding protein nutrition, with 70% of respondents unaware of how to scientifically supplement protein [8]. Group 2: Supply-Side Challenges - The domestic supply of quality protein has not kept pace with demand, with a protein self-sufficiency rate dropping from 96% to 69% between 2000 and 2021 [8]. - The dairy industry faces structural imbalances, with liquid milk accounting for 92.7% of production, while high-value products like cheese and butter make up less than 7.3% [9][10]. - The reliance on imports for key dairy ingredients, such as whey protein, poses a risk to supply stability, especially given the geopolitical uncertainties [9][10]. Group 3: Recommendations for Improvement - The article suggests that the government should create a differentiated protein intake guideline for various demographics, including infants, adults, and the elderly, to enhance consumer education [8]. - It advocates for policies that support domestic innovation in the protein industry, including tax incentives and funding for research and development [10]. - The focus should be on technological breakthroughs in dairy processing to enhance the supply chain's resilience and ensure food security [10][11]. Group 4: Technological Advancements - The company has made significant strides in dairy protein deep processing, establishing China's first automated production line for lactoferrin and developing innovative extraction technologies [11][12]. - The company has achieved 100% self-research and production capability for key dairy ingredients, creating a comprehensive technical system from research to commercialization [13]. - The advancements in technology not only improve product quality but also address the industry's long-standing issues of dependency on imports and structural imbalances [15][21]. Group 5: Holistic Approach to Nutrition and Industry - The company's strategy aims to create a closed-loop system that integrates nutrition education, industry upgrades, and self-sufficiency, ultimately benefiting both public health and the dairy sector [16][21]. - By focusing on technical innovation, the company seeks to extend its nutritional solutions beyond infant formula to cater to all age groups, addressing the broader issue of protein intake across the population [17][20].

Core Viewpoint - The event "Seeking Traces · Fresh Vitality Ceremony" held by Feihe in collaboration with Harper's Bazaar marks the launch of two new products, "Jilu" and "Qicui," which embody the concept of "fresh nutrition" and emphasize the importance of fresh raw materials in infant formula [1][10]. Group 1: New Product Launch and Innovations - Feihe has introduced a fresh raw material traceability system, allowing consumers to trace the production information of key ingredients like whey protein and lactoferrin through a simple QR code scan [3][4]. - The new products "Jilu" and "Qicui" utilize Feihe's self-produced fresh raw materials, achieving a freshness level at least 23 times higher than traditional imported ingredients [10][19]. - The traceability system signifies an upgrade in the freshness standards of the infant formula industry, marking the beginning of the third "fresh revolution" in the sector [6][8]. Group 2: Industry Leadership and Research - Feihe has established a self-controlled model by building its own farms since 2006, addressing the freshness issue at the source and setting a precedent for domestic infant formula companies [8]. - The company has been deeply involved in breast milk research for 64 years, collaborating with over 20 top research institutions globally, and has built a comprehensive breast milk database [15]. - Feihe has achieved significant recognition, holding the top position in breast milk research results, infant formula patents, and maternal source formula nutrition in China [15]. Group 3: Consumer Engagement and Brand Ambassadors - The event featured brand ambassadors Zhu Zhu and Xi Mengyao, who shared their personal experiences and emphasized the importance of transparency and safety in choosing infant formula [12][14]. - The "Star Mom Talk" segment allowed mothers to discuss the "fresh vitality" concept, reinforcing the effectiveness of Feihe's products through real user experiences [14]. Group 4: Future Directions and Industry Impact - The introduction of "Jilu" and "Qicui" represents a shift in the industry from superficial competition to a deeper focus on fresh raw material systems and product efficacy verification [19][20]. - Feihe aims to lead the infant formula industry into a new era centered on "fresh nutrition" as a core competitive advantage, influencing future purchasing standards for parents [20].

Core Viewpoint - The event "Seeking Freshness: The Fresh Vitality Ceremony" held by Feihe in collaboration with "Harper's Bazaar" marks the launch of two new products, "Jicui" and "Qicui," which embody the concept of "fresh nutrition" and emphasize the importance of fresh raw materials in infant formula [1][25]. Group 1: New Product Launch and Innovations - Feihe has introduced the world's first fresh raw material traceability system for infant formula, allowing consumers to trace the production information of key ingredients like whey protein and lactoferrin through a simple QR code scan [3][6][27]. - The new products "Jicui" and "Qicui" utilize Feihe's self-produced fresh raw materials, achieving a freshness level at least 23 times higher than traditional imported ingredients [34][41]. - The products are designed based on clinical evidence, adhering to the highest standards of randomized controlled trials (RCT) to ensure their effectiveness and safety for infants [34][41]. Group 2: Industry Impact and Standards - Feihe's innovations are seen as a driving force behind the third "freshness revolution" in the infant formula industry, redefining the standards of "freshness" and "safety" [3][25][29]. - The company has established a comprehensive control over its supply chain, from raw material sourcing to production, which enhances the transparency and quality of its products [30][32]. - Feihe's commitment to research and development has positioned it as a leader in the Chinese infant formula market, with significant achievements in maternal milk research and a robust database of over 20,000 breast milk samples [39][40]. Group 3: Brand Ambassadors and Consumer Engagement - The event featured brand ambassadors like Zhu Zhu and Xi Mengyao, who shared their personal experiences and emphasized the importance of transparency and trust in choosing infant formula [15][36]. - The engagement with mothers and industry experts during the event highlighted the growing recognition of Feihe's "fresh nutrition" philosophy and its alignment with consumer expectations for quality and safety [38][44]. - Feihe's focus on scientific feeding practices and its innovative approach to product development are expected to set new benchmarks in the industry, influencing future purchasing decisions among parents [43][44].

Summary of China Feihe Conference Call Company Overview - **Company**: China Feihe (飞鹤) - **Industry**: Infant Formula Milk Powder Key Points and Arguments Product Structure and Market Demand - Over 50% of Feihe's infant formula product structure consists of Stage 3 milk powder, which caters to children aged 1-3 years, reflecting high market demand [2][6] - The company is actively launching new products, upgrading formulas, and introducing high-end products to stabilize profit levels and meet consumer needs [2][10] Channel Distribution - The current distribution of sales channels is approximately 30% online and 70% offline, with offline maternal and infant stores being the primary revenue source [2][7] - There is a noticeable trend towards chain store development, requiring brands to offer customized products to meet channel demands [2][7] Market Competition and Strategies - The industry is facing intensified competition due to a declining population, leading to increased market pressure [2][8] - Feihe is responding by expanding into overseas markets (Canada, Vietnam, Philippines), exploring dairy raw materials and health food sectors, and continuously investing in brand development [2][8] Inventory Management - By the second half of 2025, Feihe aims to maintain channel inventory at around one month of sales, with terminal inventory at a five-year low [2][11] - The company has initiated a de-inventory process starting in mid-2025, which is expected to stabilize prices [11][16] Financial Performance - The company expects a total revenue of 21 billion yuan for 2025, a year-on-year decline [2][14] - Gross profit margin decreased in the first half of 2025 due to product structure issues and the introduction of a 1.2 billion yuan subsidy, which impacted operating expenses but not gross profit [5][18] - Net profit declined primarily due to a decrease in revenue and ongoing reductions in government subsidies [5][19] Future Outlook - Feihe anticipates a stable market share of around 18% in the second half of 2025, with plans to launch high-end new products [2][14] - The company is expected to "lighten its load" in 2026, with new products contributing positively to revenue [3][15] - Detailed plans for 2026, including revenue guidance, will be announced in March [3][15] Dividend and Share Buyback Plans - Feihe has committed to a dividend of 2 billion yuan for 2026, with 1 billion yuan already distributed in the first half of the year [5][26] - The company completed a share buyback of at least 1 billion yuan by the end of 2025, with shares held as treasury stock for employee incentive plans [5][26] Challenges and Adjustments - The company faces challenges in maintaining profitability due to the competitive landscape and the need for continued investment in customer acquisition and brand development [25][26] - Future net profit margin targets are not yet disclosed, as the company is still adjusting to current market conditions [25] Additional Important Information - The expected number of newborns in 2026 is projected to drop to over 800,000 from approximately 950,000 in 2025, which may impact industry growth [4] - The overseas business and dairy processing segments are currently at breakeven, with limited profitability due to low capacity utilization [23] - The infant formula segment is expected to recover, with improved margins anticipated for specific products [24]

Core Viewpoint - China Feihe (06186.HK) has been actively repurchasing shares, indicating strong confidence in its future growth and stability in cash flow [1][3]. Group 1: Share Buyback and Financial Strategy - On December 12, 2025, Feihe repurchased over 5.65 million shares, bringing the total repurchased shares to over 236 million, with a cumulative buyback amount exceeding 900 million HKD [1]. - In its mid-year earnings forecast on July 4, 2025, Feihe announced a plan to utilize no less than 1 billion HKD for share repurchases, targeting up to 10% of total shares [3]. - Feihe aims to maintain a stable dividend policy, expecting to distribute no less than 2 billion HKD in dividends for 2025, reflecting its robust operational cash flow [3]. Group 2: Product Innovation and Market Leadership - Feihe has maintained its position as the market leader in China's infant formula sector for six consecutive years, showcasing its role as a benchmark for high-quality development in the dairy industry [3]. - The company recently launched the "New Generation More Suitable" initiative, which includes a comprehensive upgrade across four dimensions: full industry chain, breast milk-based formula, fresh nutrition, and feeding effectiveness [3]. - Feihe introduced two new products, "Jicui" and "Qicui," which embody the "New Generation More Suitable" concept and set new freshness standards in the infant formula industry [5]. Group 3: Commitment to Social Responsibility and Innovation - Feihe has actively engaged in public welfare, contributing a total of 840 million RMB by the end of 2024, with a focus on medical, educational, and maternal-infant care initiatives [6]. - Since 2022, the company has invested over 65 million RMB in the "Support Longjiang Education Public Welfare Action," benefiting over 3.3 million teachers and students [6]. - Feihe's R&D investment has seen a compound annual growth rate of over 30% from 2018 to 2024, emphasizing its commitment to technological innovation [6].

Core Viewpoint - China Feihe (06186.HK) has been actively repurchasing shares, indicating strong confidence in its future growth and stability, alongside a commitment to maintaining dividends [4][7]. Group 1: Share Buyback and Financial Commitment - On December 12, 2025, China Feihe repurchased over 5.65 million shares, bringing the total repurchased shares to over 236 million, with a cumulative buyback amount exceeding 900 million HKD [1]. - In July 2025, the company announced a share buyback plan with a minimum of 1 billion HKD allocated for repurchases, targeting up to 10% of total shares [4]. - The company plans to maintain a stable dividend policy, expecting to distribute at least 2 billion HKD in dividends for 2025 [4]. Group 2: Market Leadership and Product Innovation - China Feihe has maintained its position as the leading brand in China's infant formula market for six consecutive years, reflecting its role as a benchmark for high-quality development in the dairy industry [4]. - The company launched a new product line, "New Generation More Suitable," which emphasizes breakthroughs in four dimensions: full industry chain, breast milk-like formula, fresh nutrition, and feeding effectiveness [4]. - The introduction of the "Fresh Nutrition System" ensures a comprehensive quality assurance system from raw milk to finished products, with 100% control over 11 core raw materials and full traceability [4]. Group 3: Social Responsibility and Technological Innovation - China Feihe has actively engaged in social responsibility initiatives, contributing 840 million CNY in donations and launching the "Support Longjiang Education Public Welfare Action," investing over 65 million CNY since 2022 [6][7]. - The company has prioritized technological innovation, with an average annual growth rate of over 30% in R&D investment from 2018 to 2024 [7]. - In 2025, China Feihe introduced "乳蛋白鲜萃提取科技" and established an international-leading database for HMOs, further enhancing its R&D capabilities [7]. Group 4: International Expansion - China Feihe is accelerating its internationalization efforts, having obtained a production license for infant formula in Canada, with products already available in over 1,500 North American retail stores [7].

Core Insights - China Feihe held its 2025 Partner Conference in Wuhan, focusing on high-quality development in the dairy industry and emphasizing the company's commitment to innovation and collaboration with partners [1][2]. Group 1: Market Position and Growth - The global infant formula market is stabilizing, with significant growth in the ultra-premium segment, driven by consumption upgrades and supportive fertility policies in China, which remains the largest market for infant formula [2]. - Feihe has established itself as a market leader by pioneering the first complete industrial chain in the industry in 2006 and leading various initiatives, including the national "14th Five-Year Plan" key projects [2][3]. Group 2: Innovation and Product Development - Feihe's "New Generation More Suitable" strategy aims to address evolving consumer needs through comprehensive breakthroughs in the supply chain, breast milk-based formulas, and active nutrition systems [3]. - The company has introduced the "Fresh Nutrition System," which utilizes fresh milk extraction technology to ensure 100% self-sufficiency in key nutrients and traceability of raw materials [3]. Group 3: Collaboration and Ecosystem - The company emphasizes a "coexistence" philosophy, fostering a win-win ecosystem with partners and aligning closely with consumer needs to drive industry progress [4]. - Feihe has recognized outstanding partners at the conference, highlighting collaborative achievements in channel expansion, marketing innovation, and service upgrades [2][4]. Group 4: International Expansion - Feihe has accelerated its internationalization, obtaining the first infant formula production license in Canada and expanding its presence in over 1,500 major supermarkets in North America, with a 270% increase in store numbers in the first half of 2025 [5]. - The company is also advancing its product offerings in Southeast Asia and focusing on adult nutrition and functional products to enhance its product matrix [5].